Амитриптилин Никомед

Quick links

Choose a section

Quick links to important sections

Advertisements

Амитриптилин Никомед

Advertisements
Advertisements

Overview of Амитриптилин Никомед

Property Description
Active ingredient Amitriptyline hydrochloride
Form Film-coated tablets
Pharmacological class Tricyclic antidepressant (TCA)
Common use Modulating mood and pain signals
Origin Synthetic, dibenzocycloheptadiene derivative

What Type of Medicine is Амитриптилин Никомед?

Амитриптилин Никомед is a synthetic pharmaceutical preparation whose primary active component is Amitriptyline hydrochloride. It is formally classified as a tricyclic antidepressant (TCA), representing an established and foundational class of psychoactive medicines.

The drug's classification as a TCA is significant because this family of medicines, designated by the ATC code N06AA09, possesses a broad action profile in the central nervous system. Tricyclic compounds are utilized for their efficacy in treating both depressive disorders and specific types of chronic pain. TCAs are clinically recognized for their capacity to address complex, long-standing conditions that require stabilization of both mood and underlying pain mechanisms. Амитриптилин Никомед itself is typically used for adult patient groups under a prescription-only (Rx) status.


Composition and Form of the Preparation

The medicine is manufactured for oral administration as a film-coated tablet, making it a highly standardized single active ingredient product.

The core of the preparation is the active substance, Amitriptyline hydrochloride, which is combined with solid pharmaceutical excipients essential for stability and proper release within the body. The form, a film-coated tablet, is specifically engineered for systemic absorption after swallowing, ensuring the ingredient reaches the central nervous system efficiently. This formulation confirms its role as an internally-acting medication, distinct from topical or liquid preparations.


Primary Purpose and Functional Principle

The high-level functional principle of Amitriptyline is to modulate crucial chemical messengers in the brain, principally serotonin and norepinephrine, to stabilize the patient's condition.

This action occurs because the drug inhibits the reuptake of these neurochemicals into nerve cells, thereby increasing their availability and promoting more balanced communication between neurons. The drug serves as a therapeutic agent for addressing significant mood problems and persistent pain syndromes, providing the foundational benefit of restoring neurochemical balance and alleviating chronic distress.

Regulatory References

  1. Tricyclic Antidepressants - NIH
  2. WHO Essential Medicines List
  3. Amitriptyline - eEML
Advertisements

What side effects are possible with Амитриптилин Никомед?

Possible Side Effects and Safety Information

The safety profile for Amitriptyline hydrochloride is organized in regulatory documents by frequency and the body system affected. Adverse reactions are classified according to official standards ranging from Very Common to Rare.

Very Common effects (affecting more than 1 in 10 users) documented in official labeling typically include somnolence (drowsiness), tremor, dizziness, dry mouth, constipation, and weight gain. These frequently observed reactions primarily involve the Nervous System and Gastrointestinal System.

Common adverse events (up to 1 in 10 users) often affect the Cardiovascular System, such as orthostatic hypotension (low blood pressure upon standing) and tachycardia (increased heart rate). Other common effects include confusion, urinary retention, and disturbances in attention.

Serious Adverse Reactions are also documented, though these may be Uncommon or Rare. Regulatory sources highlight the risk of serious cardiac arrhythmias, myocardial infarction, and seizures. Furthermore, the potential for suicidal ideation and behavior is explicitly noted, particularly in younger adults and during the initial phase of treatment or following dose adjustments.

Official safety statements include specific Population Considerations. Older adults are noted to be more susceptible to anticholinergic effects and blood pressure changes. Use is formally Contraindicated in situations such as the acute recovery phase following a myocardial infarction and in patients with severe hepatic impairment, underscoring the high-level safety restrictions defined by regulatory authorities.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severity

An overdose of Amitriptyline hydrochloride (Амитриптилин Никомед) is classified by regulatory authorities as a serious, life-threatening medical emergency. Overdose toxicity can develop rapidly, primarily affecting the central nervous system (CNS) and the cardiovascular system.

Documented CNS manifestations include profound coma, respiratory depression, and seizures (convulsions), along with stupor, confusion, and extreme drowsiness. Anticholinergic signs such as dilated pupils, urinary retention, and dry mouth are also noted. The most serious outcomes are severe cardiovascular toxicity, including life-threatening ventricular dysrhythmias, severe hypotension, and characteristic QRS complex prolongation on an ECG. Elderly patients may also be at increased risk for developing low salt (sodium) levels in the blood, which can present with confusion or convulsions.

Mandatory Emergency Action

Official guidance mandates that the individual seek immediate medical attention and contact emergency services right away if an overdose is suspected. Hospitalization is required due to the rapid onset and severity of the documented clinical signs.

Management is symptomatic and supportive, as no specific antidote is known. Regulatory guidelines document the need for continuous cardiac monitoring for a minimum of six hours and the use of procedures such as activated charcoal and intravenous sodium bicarbonate to manage specific documented cardiac effects.

Advertisements

Therapeutic Uses of Амитриптилин Никомед

What Амитриптилин Никомед Treats: Main Uses and Benefits

Therapeutic Domains and Symptom Management

Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Amitriptyline

Regulatory documents strictly define the patient populations eligible to use Amitriptyline hydrochloride (Амитриптилин Никомед), primarily focusing on adults. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the drug, those in the acute recovery phase following myocardial infarction, or individuals with pre-existing disorders of cardiac rhythm or heart block. It is also contraindicated in patients with severe liver disease and those who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Use is not recommended for certain age groups. Safety and efficacy have not been established in children and adolescents under 18 years of age for all indications, and use is explicitly contraindicated in children under 6 years. Older adults (65 and over) are eligible but require lower starting doses and special care due to increased susceptibility to effects like orthostatic hypotension.

Conditional Use and Restrictions

Pregnancy and Lactation: Use is generally not recommended during the first and third trimesters of pregnancy. The drug is excreted into human milk, making its use not recommended while breastfeeding. Caution and close supervision are required for patients with comorbidities like angle-closure glaucoma, a history of seizures, urinary retention, or hyperthyroidism, as the drug may exacerbate these conditions.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile

The interactions associated with Amitriptyline are primarily defined by mandated prohibitions and alterations to the medicine’s exposure. The co-administration of this medicine with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the high risk of severe conditions, notably Serotonin Syndrome. A mandatory 14-day separation period must be observed when switching from an irreversible MAOI before starting this medication. Further contraindicated combinations include Cisapride, Pimozide, and Thioridazine due to documented risks of cardiac arrhythmias.

Pharmacokinetic Interactions are significant, as the medicine is metabolized by the CYP2D6 and CYP2C19 enzyme systems. Regulatory documentation notes that co-administration with strong CYP2D6 inhibitors (e.g., fluoxetine) can inhibit metabolism and lead to higher plasma concentrations. Conversely, enzyme inducers (e.g., Rifampicin, Carbamazepine) may reduce overall exposure.

Pharmacodynamic Interactions include the documented enhancement of sedative effects when combined with CNS Depressants, including alcohol. There is also an increased risk of severe antimuscarinic effects when co-administered with other anticholinergic agents. Population-specific considerations exist for Hyperthyroid patients due to increased cardiac risks and for diabetic patients due to potential modification of glucose responses.

Advertisements

Mechanism of Action

Dual Modulation of Key Neurotransmitter Transporters

This core mechanism involves the inhibition of reuptake at both the Serotonin Transporter ( SERT) and Norepinephrine Transporter ( NET). By increasing the functional availability of these chemical messengers, the drug influences the long-term regulation of central signaling activity and enhances the activity of monoamine-driven descending inhibitory pathways in the CNS.

Blockade of Neuronal Signaling Components

The drug exerts effects with fast-acting kinetics by physically blocking voltage-gated sodium ( Na^+) channels on nerve cell membranes, which alters the electrical excitability of neurons and limits excessive firing. Concurrently, it functions as an antagonist at central Histamine H1 receptors, leading to a direct and immediate reduction in central arousal activity.

Dynamic of Delayed Physiological Adaptation

The complete physiological adaptation resulting from this mechanism is not immediate; it requires chronic cellular change. While molecular binding is rapid, the resulting long-term functional changes, such as the regulation of neurotrophic factors and the ultimate rebalancing of regulatory feedback circuits, cause the full adaptive change in signaling circuits to manifest over several weeks.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Амитриптилин Никомед

The use of Amitriptyline (the active ingredient in Амитриптилин Никомед) follows a structured protocol focused strictly on procedural administration. The medicine is authorized for oral administration as a film-coated tablet, which can be taken with or without food. Tablets must be swallowed whole with water as a standard preparation requirement.

Dosing Principles and Regimens

The standard protocol requires beginning treatment at a low dose, followed by a gradual increase—a process known as titration. The dose is most often administered as a single dose at bedtime or in the evening due to procedural considerations.

Indication Initial Daily Dose (Adult Outpatient) Maximum Daily Dose (Adult Outpatient)
Depression 50 mg to 100 mg at bedtime or 75 mg divided 150 mg
Chronic Pain 10 mg to 25 mg in the evening 100 mg (used with caution)

Dose adjustments are typically made in 25 mg or 50 mg increments, increasing gradually every few days until the target range is reached.

Use Patterns and Withdrawal

Administration is structured as a long-term course, with maintenance therapy typically required for at least three months to ensure adherence to the full treatment protocol. Withdrawal from the medicine is a mandated procedural step requiring a gradual dose reduction over several weeks. Official labeling dictates that a lower starting dose (e.g., 10 mg to 25 mg daily) and a reduced maximum dose are required for older adults (65 years and older) and patients with hepatic impairment. A 14-day washout period is a critical procedural constraint when switching a patient from a Monoamine Oxidase Inhibitor (MAOI).

Advertisements

Recent Clinical Evidence

Амитриптилин Никомед: Overview of Clinical Evidence


Evidence for use in Major Depressive Disorder

Research has explored this medicine using short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating symptoms in adult patients who were experiencing major depressive episodes. Studies monitored how symptoms evolved using standardized rating scales to measure changes in symptom severity. Findings reported measured symptom change over short assessment periods, generally not exceeding three months. However, the certainty of the findings in systematic reviews is often characterized as low or very low, reflecting that long-term effects are not fully established, and quality of life outcomes are sparsely reported.


Evidence for use in Chronic Neuropathic Pain

Studies have examined this medicine using short-term, double-blind controlled designs to explore outcomes related to physical discomfort associated with nerve damage, such as diabetic neuropathy and post-herpetic neuralgia. Researchers examined pain intensity and changes in daily functioning. Observed findings were associated in some studies with changes in outcomes related to physical discomfort. Many supporting trials are older and involved modest sample sizes, suggesting that the certainty of the evidence may be limited according to contemporary research standards.


Evidence Gaps and Areas of Uncertainty

Research has also explored this medicine in studies of the prophylactic management of chronic headaches and in studies of nocturnal enuresis in children aged six years and above. For all indications, data are still emerging regarding the measured effect on a patient's overall quality of life. Comparative evidence against many newer therapeutic options is lacking. The research base does not provide insight into outcomes of study observation beyond specified maximum durations for some pediatric uses, and data for certain groups, such as the frail elderly, remains insufficient.

Key Studies & References Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006 (Nocturnal Enuresis)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Амитриптилин Никомед (FAQ)


Q: How quickly can a person expect to feel the effects of Амитриптилин Никомед?

A: The effects are generally experienced in two phases. Initial effects, such as feelings of sedation or drowsiness, may occur within the first hours or days of treatment. However, the full therapeutic benefit for addressing mood or chronic pain typically takes much longer, often manifesting over several weeks or sometimes up to two months, as the body adjusts to the changes in chemical messengers.


Q: Is Амитриптилин Никомед considered addictive or habit-forming?

A: Official medical consensus indicates that Амитриптилин Никомед is not considered to be an addictive or habit-forming medicine. However, because the body adapts to the presence of the drug over time, stopping its use suddenly can lead to physical reactions known as discontinuation syndrome. Regulatory documents therefore describe the need for a gradual dose reduction when discontinuing treatment.


Q: How does the action of Амитриптилин Никомед compare to newer antidepressants (SSRIs)?

A: Амитриптилин Никомед belongs to an older class of drugs called Tricyclic Antidepressants (TCAs). Its action is described as broad, influencing multiple brain messengers like serotonin and norepinephrine, and blocking several other receptors. Newer drugs like SSRIs (Selective Serotonin Reuptake Inhibitors) are designed to act more selectively, focusing primarily on increasing the availability of serotonin.


Q: Is it necessary to have regular medical tests (e.g., blood work) while taking Амитриптилин Никомед?

A: Regulatory information does not explicitly list all required tests. However, official sources describe monitoring for potential cardiac changes, such as ECGs, and checking for anticholinergic side effects (like eye pressure and mental status) as part of required supervision, particularly in certain patient groups.


Q: Are there any known long-term side effects associated with continuous use of Амитриптилин Никомед?

A: Some common side effects, such as weight gain, dry mouth, and constipation, are documented and may persist with continuous long-term use. Official safety documents also contain caution regarding an increased risk of bone fractures linked to the use of Tricyclic Antidepressants.


Q: Is it possible to experience withdrawal symptoms when stopping Амитриптилин Никомед?

A: Yes, if the medicine is stopped abruptly, an individual may experience discontinuation symptoms. These can be flu-like (nausea, muscle pain) or involve psychological effects like restlessness and trouble sleeping. Official guidance describes a gradual dose reduction over several weeks as a necessary procedure to minimize the risk of these symptoms.


Q: Does Амитриптилин Никомед affect a person's ability to drive or operate machinery?

A: Official patient information explicitly cautions against driving or operating machinery until it is known how the medicine affects an individual. This warning is due to the documented common side effects of drowsiness, dizziness, and disturbed concentration, which can significantly impair reaction time and attention.


Q: Are there any specific foods or drinks that should be avoided while taking Амитриптилин Никомед?

A: Official interaction information strongly advises against the consumption of alcohol, as it can dangerously increase the medicine's sedative effects, leading to excessive drowsiness. The tablets can otherwise generally be taken with or without food.


Q: What is the risk of having a serious drug interaction with common over-the-counter medications?

A: Official sources note an increased risk of side effects when this medicine is combined with other drugs that cause sedation or have an anticholinergic action. This may include certain over-the-counter antihistamines or sleep aids. Furthermore, the use of the herbal supplement St John's wort is officially listed as contraindicated.


Q: Is Амитриптилин Никомед safe for use in older patients (geriatric population)?

A: Official eligibility documents state that use in older adults (aged 65 and over) requires specific caution and close supervision. This population is generally more susceptible to side effects like confusion, dry mouth, and low blood pressure upon standing. For this reason, a lower starting dose is usually specified in regulatory documents for this group.


Q: What is the risk of having blurred vision or other eye-related side effects?

A: Blurred vision is a documented side effect, which is often linked to the medicine’s anticholinergic properties. Official sources also caution about the risk of increasing intraocular pressure and exacerbating a pre-existing condition such as angle-closure glaucoma.


Q: Can taking Амитриптилин Никомед cause problems with sleep, such as nightmares or insomnia?

A: While the medicine is often associated with drowsiness (somnolence), official safety documentation also lists disturbances like insomnia (sleeplessness) and unusually vivid dreams or nightmares among the possible adverse effects.


Q: Is there a period of time where a patient's mood might feel worse before feeling better?

A: Regulatory documents note that during the initial phase of treatment or following a change in dose, there is an officially recognized risk of worsening depression. This includes the emergence of suicidal thoughts or behaviors, particularly in younger adults, until the drug's intended therapeutic effect has stabilized.


Q: Does Амитриптилин Никомед have a Black Box Warning, and what does it concern?

A: Yes, the medicine is accompanied by the FDA's most serious warning, known as a Boxed Warning. This warning highlights the increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to age 24) when starting treatment or following a dose adjustment.


Q: What should be done if a patient misses a dose of Амитриптилин Никомед?

A: Instructions usually specify that if a dose is missed, it can be taken as soon as it is remembered, unless it is close to the time for the next scheduled dose. However, if the medicine is taken as a single dose at bedtime, the patient should not take a missed dose the following morning but should wait until the next evening to take the regular dose.


Q: Is it true that this medicine can make the skin more sensitive to the sun?

A: Yes, official documentation lists photosensitization, which is an increased sensitivity of the skin to sunlight, as a potential allergic side effect of this medicine. Due caution regarding sun exposure may therefore be necessary.


Q: Does the medicine affect sexual function or libido?

A: Official patient information indicates that the medicine can cause changes to sexual function and sex drive. Reported effects include a decrease in libido or difficulties with erection or ejaculation in men.


Q: What should a patient know about taking Амитриптилин Никомед before surgery, including dental work?

A: Official regulatory guidance advises patients to inform their doctor or dentist that they are taking this medication if they are scheduled to receive either general or local anesthetics for any procedure. This is a necessary safety precaution for procedures, including dental work.


Q: Can this drug interact with herbal supplements or natural remedies?

A: Official sources specifically caution against the use of the herbal supplement St John's wort due to the risk of dangerous drug interactions. The label also notes potential interactions with other supplements that may affect certain liver enzyme systems (CYP2D6 or CYP2C19).


Q: Does Амитриптилин Никомед treat anxiety, or is it mainly for depression?

A: The medicine is officially approved for the treatment of major depressive episodes and certain types of neuropathic pain in adults. While it belongs to a class of drugs that may be used by medical professionals for other purposes, anxiety is not listed as a primary approved indication on the core regulatory labels.


Q: Is constipation a common side effect of Амитриптилин Никомед, and why?

A: Constipation is documented as a very common side effect in official information. This effect is generally linked to the medicine's anticholinergic action, which involves blocking nerve signals that control various involuntary functions, including the movement of muscles in the digestive tract.


Q: Can the medication cause a feeling of restlessness or agitation?

A: Yes, while the medicine is primarily known for its sedative effects, official safety documentation lists both restlessness and agitation as possible side effects.


Q: What are the signs of a serious allergic reaction to Амитриптилин Никомед?

A: Signs of a serious allergic reaction documented in regulatory information include skin reactions such as hives or rash, swelling of the face, lips, or tongue, and difficulty breathing or tightness in the throat.


Q: Are there specific symptoms that signal a potential problem with the liver?

A: Official safety documents list rare but serious signs that may indicate a potential liver problem. These include the development of jaundice (yellowing of the eyes or skin) and the appearance of dark urine.


Q: Does Амитриптилин Никомед have an active metabolite?

A: Yes, once taken, the medicine is processed by the liver into an active substance called nortriptyline. This substance is itself a tricyclic antidepressant and contributes to the overall therapeutic effect and duration of action of the medication.


Q: Does the official information mention any effect on fertility or conception?

A: Official patient information explicitly states that there is no evidence that this medicine affects fertility in either men or women.


Q: What are the signs of a potential overdose of Амитриптилин Никомед?

A: Signs of a potential overdose are severe and require immediate medical attention. They include irregular or rapid heartbeat, coma, seizures, severe confusion, hallucinations, severely low blood pressure, and dilated pupils.

Advertisements

How should Амитриптилин Никомед be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Амитриптилин Никомед — Official Regulatory Information

Storage & Disposal Scope Requirements (Official Labeling)
Labeled Storage Temperature Store at controlled room temperature (20 C to 25 C), protecting from excess heat and freezing.
Light/Moisture Protection Must be kept in a dry place, away from direct light and moisture (e.g., not in the bathroom).
Packaging/Container Rules Keep the medication in the original container, tightly closed.
Child-Protection Storage Store the product out of the reach and sight of children. Always secure safety caps and place in a safe location.
Disposal Instructions The preferred method is to use a drug take-back program or authorized collection site. If unavailable, mix the medicine with an undesirable substance (e.g., dirt, coffee grounds), seal it in a container, and discard in the household trash. Do not flush down the toilet.

Connection to the Overall Storage/Disposal Profile

Official regulatory documents define the storage profile of this drug by mandating controlled room temperature and protection from specific environmental factors (light, moisture, freezing) to ensure chemical stability. These documents strictly prescribe keeping the product sealed in its original container and enforcing child-safety measures. Labeled disposal procedures must be followed to avoid environmental contamination and prevent potential misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Амитриптилин Никомед found in:

A-Z Index: